NICE expands reach of Erbitux in colorectal cancer

2nd March 2017 Uncategorised 0

Cost regulators for the NHS treatments in England and Wales are expanding the scope of Merck’s Erbitux so that the therapy will be routinely available to treat a wider range of patients with metastatic colorectal cancer (mCRC).
Source: News